Clinical trials: Oral Anticoagulants
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Atrial Fibrillation
Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation
We will compare long-term effectiveness and safety in patients with atrial fibrillation treated with left atrial appendage occlusion versus new oral anticoagulants to prevent ischemic stroke from multicenter registry data
- Trial name
- NCT03108872
- Testing
- left atrial appendage occlusion, New oral anticoagulants
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Sejong General Hospital
Atrial Fibrillation, Deep Vein Thrombosis
Pilot Study: Comparison of Patients' Knowledge of Direct Oral Anticoagulants in Post-hospitalization Between 2 Cardiology Departments Offering or Not a Pharmaceutical Interview During Hospitalization
Direct oral anticoagulants (Rivaroxaban, Apixaban and Dabigatran) are an alternative to anti-vitamin K drugs and low molecular weight heparins in many cardiovascular diseases.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- EDUC-AOD (NCT04674202)
- Testing
- Phone interview
- Where
- 2 sites in France
- Volunteers
- 154 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
Ischemic Stroke, Oral Anticoagulation
Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants
The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or…
- Conditions
- Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment
- Trial name
- ASPERA (NCT06823466)
- Where
- 47 sites in Croatia, Denmark and 13 more
- Volunteers
- 200 people
- Sponsor
- University of L'Aquila
Atrial Fibrillation
New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study
Several new oral direct anticoagulants have been recently marketed. However, only a few, limited, studies have provided data about the pharmacology of new oral direct anticoagulants in older persons.
- Trial name
- ADAGE (NCT02464488)
- Testing
- Plasma drug concentrations
- Where
- 2 sites in France
- Volunteers
- 232 people
- Sponsor
- Hôpital Charles Foix
Stroke, Atrial Fibrillation
New Oral Anticoagulants (NOAC) in Stroke Patients
Registry to explore characteristics, use and management of new oral anticoagulants (NOAC) and vitamin K antagonists (VKA) treatment among patients with atrial fibrillation (AF) and recent cerebrovascular disease in a "real-world"…
- Trial name
- NOACISPLongTer (NCT03826927)
- Testing
- treatment with NOACs or VKAs
- Where
- 2 sites in Switzerland
- Volunteers
- 1,023 people
- Sponsor
- University Hospital, Basel, Switzerland
Atrial Fibrillation
Pill-in-the-POCKET Oral Anticoagulation Strategy After AF Catheter Ablation
The clinical benefit of pill-in-the-POCKET anticoagulation after atrial fibrillation catheter ablation remains uncertain. We aimed to evaluate the clinical benefit and safety of pill-in-the-POCKET anticoagulation after atrial…
- Trial name
- POCKET-OAC (NCT06216769)
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Seoul National University Hospital
Pacemaker Implantation, Pocket Hematoma and Bleeding
Pocket Haematoma Prevention in Patients Who Required Implantation/Replacement of a Pacemaker or Implantable Cardiac Defibrillator. The PHP Study.
The aim of this study is to demonstrate the efficacy of fibrin sealant (Tissucol-Baxter) in preventing pocket haematoma and subsequent complications in patients undergoing pacemaker or ICD implantation/replacement which cannot…
- Conditions
- Pacemaker Implantation, Pocket Hematoma and Bleeding, Antiplatelet Therapy or Oral Anticoagulants
- Trial name
- PHP (NCT01127984)
- Testing
- tissucol, drainage system
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Careggi Hospital
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University
Tooth Extraction
Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction
In patients treated with direct oral anticoagulants, bleeding events during or after tooth extraction can lead to unscheduled interruption of the antithrombotic treatment and a potential increased risk of thrombo-embolic events.
- Trial name
- EXTRACT-NOAC (NCT03413891)
- Testing
- Tranexamic Acid
- Where
- Belgium
- Volunteers
- 222 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atrial Fibrillation (AF)
Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual)
The purpose of the PAUSE-Virtual Study is to show that by changing pre-surgery visits with patients taking a blood thinner (direct oral anticoagulant (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) when the participant…
- Trial name
- PAUSEVirtual (NCT06844227)
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 1,780 people
- Sponsor
- McMaster University
Femur Fracture
Assessment of a Procedure for Managing Oral Anticoagulants (NACO) in the Management of Fractures
The purpose of this study is to demonstrate that by allowing patients with an anticoagulant level less than 100 ng/ml to have their fracture managed surgically, will reduce the delay in surgery and therefore the complications…
- Trial name
- STOP-NACO (NCT06220422)
- Testing
- Standard Department procedure for managing direct-acting oral anticoagulants, New Department procedure for managing direct-acting oral anticoagulants
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Hôpital NOVO
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Anticoagulant Therapy
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation.
- Trial name
- PHAPOCU (NCT05491460)
- Testing
- Apixaban 5 MG Tab, Dabigatran 150 MG Tab, Edoxaban 60Mg Tab
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Doasense GmbH
Non-valvular Atrial Fibrillation
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
To assess the safety and pharmacokinetics of DU-176b administered to non-valvular atrial fibrillation patients with severe renal impairment, compared with DU-176b administered to non-valvular atrial fibrillation (NVAF) patients…
- Trial name
- NCT01857622
- Testing
- DU-176b 15mg, DU-176b 30mg, DU-176b 60mg
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Venous Thromboembolism
Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.
- Trial name
- NCT00689520
- Testing
- tinzaparin, acenocoumarol
- Where
- 2 sites in Spain
- Volunteers
- 241 people
- Sponsor
- Hospital Universitari de Bellvitge
Diabetes
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
Diabetic and nondiabetic patients will be evaluated if they had a first diagnosis of non-valvular atrial fibrillation and in therapy with non-vitamin K oral anticoagulants and with vitamin K oral anticoagulants.
- Trial name
- ORGANON (NCT02935855)
- Testing
- Dabigatran, Apixaban, Rivaroxaban
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Pavia
Embolism and Thrombosis, Hemorrhage
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
The purpose of this study is to investigate the preventability of serious adverse drug reactions (ADRs) related to the use of direct oral anticoagulants (DOACs).
- Trial name
- ADR-OAC (NCT02720328)
- Testing
- Blood samples for DOAC measurement
- Where
- 2 sites in Belgium
- Volunteers
- 102 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Acute Myocardial Infarction, Unstable Angina
PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy
Approximately 5 to 8% of patients undergoing percutaneous coronary interventions requires chronic anticoagulant therapy due to atrial fibrillation or other clinical entities.
- Conditions
- Acute Myocardial Infarction, Unstable Angina, Chronic Stable Angina
- Trial name
- PERSEO (NCT03392948)
- Where
- 10 sites in Italy
- Volunteers
- 1,080 people
- Sponsor
- Italian Society of Invasive Cardiology